Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156


Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies.

Juloori A, Shah C, Stephans K, Vassil A, Tendulkar R.

Prostate Cancer. 2016;2016:2420786. doi: 10.1155/2016/2420786. Epub 2016 May 23. Review.


Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.

Bracci S, Osti MF, Agolli L, Bertaccini L, De Sanctis V, Valeriani M.

Radiat Oncol. 2016 Jun 8;11(1):78. doi: 10.1186/s13014-016-0656-0.


The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures.

Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, Hao M, Ye L, Wu X, Yang C.

PLoS One. 2016 May 12;11(5):e0154499. doi: 10.1371/journal.pone.0154499. eCollection 2016.


Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Abusamra A, Murshid E, Kushi H, Alkhateeb S, Al-Mansour M, Saadeddin A, Rabah D, Bazarbashi S, Alotaibi M, Alghamdi A, Alghamdi K, Alsharm A, Ahmad I.

Urol Ann. 2016 Apr-Jun;8(2):123-30. doi: 10.4103/0974-7796.176872. Review.


Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study.

Kang HJ, Kay CS, Son SH, Kim M, Jo IY, Lee SJ, Lee DH, Suh HJ, Choi YS.

Radiat Oncol J. 2016 Mar;34(1):45-51. doi: 10.3857/roj.2016.34.1.45. Epub 2016 Mar 30.


Near-infrared fluorescence imaging platform for quantifying in vivo nanoparticle diffusion from drug loaded implants.

Markovic S, Belz J, Kumar R, Cormack RA, Sridhar S, Niedre M.

Int J Nanomedicine. 2016 Mar 24;11:1213-23. doi: 10.2147/IJN.S93324. eCollection 2016.


Radioresistance of Brain Tumors.

Kelley K, Knisely J, Symons M, Ruggieri R.

Cancers (Basel). 2016 Mar 30;8(4). pii: E42. doi: 10.3390/cancers8040042. Review.


Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine.

Dulaney CR, Osula DO, Yang ES, Rais-Bahrami S.

Prostate Cancer. 2016;2016:4897515. doi: 10.1155/2016/4897515. Epub 2016 Feb 16. Review.


Prostate cancer: Case volume and improved outcomes across cancer care.

Narang AK, Tran PT.

Nat Rev Urol. 2016 Apr;13(4):186-7. doi: 10.1038/nrurol.2016.15. Epub 2016 Feb 2. No abstract available.


Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.

Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D.

Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395.


Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.

Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M 3rd, Gottschalk AR.

Radiat Oncol. 2016 Jan 21;11:8. doi: 10.1186/s13014-016-0585-y.


Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia.

Peacock M, Quirt J, James Morris W, So A, Sing CK, Pickles T, Tyldesley S.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):409-13. doi: 10.5489/cuaj.3288. Epub 2015 Dec 14.


Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.

Peach MS, Showalter TN, Ohri N.

Prostate Cancer. 2015;2015:624736. doi: 10.1155/2015/624736. Epub 2015 Nov 30. Review.


Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Arcangeli S, Agolli L, Donato V.

Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):425-9. doi: 10.1016/j.rpor.2014.08.001. Epub 2014 Sep 10. Review.


Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?

Murray JR, McNair HA, Dearnaley DP.

Cancer Manag Res. 2015 Nov 11;7:331-44. doi: 10.2147/CMAR.S51955. eCollection 2015. Review.


Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted".

Zaorsky NG, Hallman MA, Smaldone MC.

Ann Transl Med. 2015 Oct;3(18):274. doi: 10.3978/j.issn.2305-5839.2015.09.14. No abstract available.


Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.

Xiang M, Nguyen PL.

Brachytherapy. 2015 Nov-Dec;14(6):773-80. doi: 10.1016/j.brachy.2015.09.004. Epub 2015 Oct 17.


Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.

Kumabe A, Fukuhara N, Utsunomiya T, Kawase T, Iwata K, Okada Y, Sutani S, Ohashi T, Oya M, Shigematsu N.

Radiat Oncol. 2015 Oct 12;10:208. doi: 10.1186/s13014-015-0515-4.


A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer.

Potharaju M, Subramanaiam R, Venkataraman M, Perumal K, Ramakrishnan B, Vangara R, Reddy S.

Cureus. 2015 Aug 14;7(8):e303. doi: 10.7759/cureus.303.


3D Porous Chitosan-Alginate Scaffolds as an In Vitro Model for Evaluating Nanoparticle-Mediated Tumor Targeting and Gene Delivery to Prostate Cancer.

Wang K, Kievit FM, Florczyk SJ, Stephen ZR, Zhang M.

Biomacromolecules. 2015 Oct 12;16(10):3362-72. doi: 10.1021/acs.biomac.5b01032. Epub 2015 Sep 16.

Items per page

Supplemental Content

Write to the Help Desk